


CellVec to strengthen manufacturing and supply capacity of lentiviral vectors

07 October 2021 | News

Enters strategic partnership with Australia's Peter MacCallum Cancer Centre to manufacture and supply lentiviral vectors for cell-based immunotherapies for the treatment of cancer



Southeast Asia's first GMP-compliant CDMO for viral vector manufacturing CellVec Pte Ltd has entered a strategic partnership with Australia's Peter MacCallum Cancer Centre (Peter Mac) to manufacture and supply lentiviral vectors for their in-house pipeline of cell-based immunotherapies for the treatment of cancer.

In CellVec's first strategic relationship with a leading Australian cancer research center, the partnership connects the regional specialist in viral vector manufacturing and the leading integrated cancer institution, marking a significant milestone.

Peter Mac and CellVec are co-located in the Asia Pacific region and present an opportunity to partner locally to overcome crucial components of cell-based immunotherapy manufacturing and supply. It also enables a pipeline of high-potential research focused on developing the next generation of immunotherapies.

Established within the regional biotechnology hub of Singapore, CellVec was awarded GMP certification in 2020 by the Health Sciences Authority. Its state-of-the-art facility is designed in line with PIC/S, US FDA and EU GMP specifications, ensuring compliant biosafety containment and aseptic processing conditions for the manufacturing of viral vectors.

Vector Platform: It comprises GMP-compatible molecular expression helper plasmids with sequences optimized in-house, third-generation self-inactivating lentiviral vectors, a GMP HEK293T Master Cell Bank and an efficient validated manufacturing process, which ensures improved production yields and high process consistency while adhering to the highest standards of manufacturing quality.

Dr. Lucas Chan, Chief Scientific Officer of CellVec says, “the partnership with Peter Mac underscores CellVec’s capability to support and accelerate clinical development of Advanced Cell and Gene Therapies and reaffirm Singapore’s position as an advanced hub for viral vector development, manufacture, logistics and supply.